Fig. 4: Validation of the interaction between circSARS-CV2-N1368 and miR-103a-3p. | Acta Pharmacologica Sinica

Fig. 4: Validation of the interaction between circSARS-CV2-N1368 and miR-103a-3p.

From: CircSARS-CV2-N1368 from SARS-CoV-2 impairs endothelial cell function through the upregulation of ATF7 to activate TLR4/NF-κB/ROS signaling

Fig. 4

a The potential binding sites of 5 miRNAs in circSARS-CV2-N1368. b Identifcation of the interactions between 5 miRNAs and circSARS-CV2-N1368 by RNA pull-down assay (1-way ANOVA, n = 3 per group). c Identification of the binding site of miR-103a-3p in circSARS-CV2-N1368 by dual luciferase assay (1-way ANOVA, n = 3 per group). d RIP assay was performed by using anti-AGO2 antibody, and the enrichment of circSARS-CV2-N1368 and miR-103a-3p was determined by RT-qPCR assay. e Detection of circSARS-CV2-N1368 level in HCMECs with transfection of miR-103a-3p. f Detection of miR-103a-3p level in HCMECs with overexpression of circSARS-CV2-N1368, and in HCMECs exposed to TNF-α (g) and OGD treatment(h), respectively. Comparisons were made with unpaired t test, n = 3 per group in (d)–(h). *P < 0.05, **P < 0.01, ***P < 0.001.

Back to article page